Drug intelligence / Profile preview

SOB-201

Development stage: Unknown
Lead developer: Shine-On Biomedical
Modality: Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems

Overview

SOB-201 is an exosome-based investigational therapy developed by Shine-On BioMedical. It is currently in the discovery phase and has not yet entered clinical trials. The drug is being explored for use in nervous system diseases and cardiovascular diseases, with stroke as its primary active indication. As an exosome therapy, SOB-201 likely leverages the natural intercellular communication properties of exosomes to deliver therapeutic effects, although specific mechanisms of action have not been disclosed[1].

Beyond the preview

Go deeper on SOB-201.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SOB-201.

Explore the full profile